REFERENCES
- Beylot C. La séborrhée et ses complications. Rev Prat 1993; 43: 2320–7
- Burton J L, Shuster S. The relationship between seborrhea and acne vulgaris. Br J Dermatol 1971; 85: 197–8
- Piérard-Franchimont C, Piérard G E, Kligman A M. Rhythm of sebum excretion during the menstrual cycle. Dermatologica 1991; 182: 211–13
- Coenen C MH, Thomas C MG, Borm G F, et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996; 53: 171–6
- Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, et al. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil 1996; 41: 423–9
- Mango D, Ricci S, Manna P, et al. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception 1996; 53: 163–70
- Palatsi R, Hirvensalo E, Liukko P, et al. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol (Stockh) 1984; 64: 517–23
- Kloosterboer H J, Vonk-Noordergraaf C A, Turpijn E W. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception 1988; 38: 325–32
- Bergink E W, van Meel F, Turpijn E W, et al. Binding of progestagens to receptor proteins in MCF-7 cells. J Steroid Biochem 1983; 19: 1563–70
- Elger W, Steinbeck H, Schillinger E, et al. Endocrine pharmacological profile of gestodene. Gestodene: Development of a New Gestodene-containing Low-dose Oral Contraceptive. Parthenon Publishing, Carnforth, UK 1987; 19–33, Proceedings of a special satellite symposium held in conjunction with the XIth World Congress of Gynecology and Obstetrics
- Bilotta P, Favilli S. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive. Arzneim-Forsch/Drug Res 1988; 38: 932–4
- Halbe H W, de Melo N R, Bahamondes L, et al. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care 1998; 3: 113–20
- Levrier M, Degrelle H, Bestaux Y, et al. Efficacite sur l'acne des contraceptifs oraux. Rev Fr Gynecol Obstet 1988; 83: 573–6
- Ferguson H, Vree M L, Wilpshaar J, et al. Multicenter study of the efficacy, cycle control and tolerability of a desogestrel-containing triphasic oral contraceptive. Eur J Contracept Reprod Health Care 2000; 5: 1–11
- Wilhelm K-P, Elsner P, Berardesca E, . Use of Sebutape® assessed by image analysis to measure sebaceous gland activity. Bioengineering of the Skin: Skin Surface Imaging and Analysis, K-P Wilhelm, P Elsner, E Berardesca, et al. CRC Press, Boca Raton 1996, Chapter 8
- World Health Organization. WHO Adverse Reaction Dictionary. WHO Collaborating Centre for International Drug Monitoring, UppsalaSweden 1996, Version 3
- Redmond G P, Olson W H, Lippman J S, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized placebo-controlled trial. Obstet Gynecol 1997; 89: 615–22
- Lucky A W, Henderson T A, Olson W H, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997; 37: 746–54
- Lever L, Marks R. Current views on the aetiology, pathogenesis and treatment of acne vulgaris. Drugs 1990; 39: 681–92
- Goldzieher J W, Moses L E, Averkin E, et al. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril 1971; 22: 609–23
- Redmond G, Godwin A J, Olson W, et al. Use of placebo controls in an oral contraception trial: methodological issues and adverse event incidence. Contraception 1999; 60: 81–5